COMMUNIQUÉS West-GlobeNewswire

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
15/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, [...]
Obalon Schedules Fourth Quarter and Year End 2018 Financial Results Conference Call for February 22, 2019 at 8:30 a.m. Eastern Time
15/02/2019
SAN DIEGO, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon [...]
Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern
15/02/2019
Management to Provide Update on Strategic Acquisitions, Financing, Growth Initiatives & Spin Out of NuGenerex Immuno-Oncology MIRAMAR, FL, Feb. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology [...]
Dragon Jade Enters MOU for Stake in Connaissance Holdings
15/02/2019
HONG KONG, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Dragon Jade International Limited (“Dragon Jade” or “the Company”) (OTCQX: DGJI), today announced that it has entered into a memorandum of understanding (“MOU”) to acquire up [...]
Xbrane Biopharma AB informs about presentations where the company participates on February 19
15/02/2019
Press release 2019-02-15 During Tuesday, February 19, Xbrane will attend two presentations that will also be webcasted live. Below follows information about the events and links to the webcasts that will also be [...]
Extendicare Announces February 2019 Dividend of C$0.04 per Share
15/02/2019
MARKHAM, Ontario, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
Predictive Technology Group Reports Second Quarter Fiscal 2019 Financial
15/02/2019
Revenue jumps 216% for the quarter to $10.7 million versus the prior year; and up 246% for the six month period to $18.8 million with $2.0 million in positive cash flow from operations SALT LAKE CITY, Feb. 15, 2019 ( [...]
Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
15/02/2019
JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz [...]
Hoth Therapeutics Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “HOTH”
15/02/2019
NEW YORK, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications [...]
Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH)
15/02/2019
Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF antibody) used in combination with CAR- [...]
CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
15/02/2019
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar [...]
Neuronetics, Inc. Announces Appointment of Dr. Cheryl R. Blanchard to its Board of Directors
15/02/2019
Dr. Blanchard brings more than 30 years of medical device and biotechnology experience to Neuronetics MALVERN, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical [...]
Repligen to Report Fourth Quarter and Full Year 2018 Financial Results
15/02/2019
- Webcast and Conference Call to Be Held Thursday, February 21, 2019 at 8:30 a.m. EST - WALTHAM, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report [...]
Myriad Applauds the American Society of Breast Surgeons New Guidelines Recommending Genetic Testing for All People with Breast Cancer
15/02/2019
SALT LAKE CITY, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced its support of the American Society of Breast Surgeons (ASBrS) new [...]
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco
15/02/2019
YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will [...]
Aleafia Health Announces new President of Clinic Operations
15/02/2019
White to Lead Integration of Canabo Medical Clinics and GrowWise Health Post-closing of Emblem Acquisition Previously the COO of Canada’s Largest Multidisciplinary Clinic Network TORONTO, Feb. 15, 2019 (GLOBE NEWSWIRE [...]
Cerecor Announces CERC-301 Granted U.S. Patent
15/02/2019
ROCKVILLE, Md., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in [...]
Achaogen Announces Pricing of $15 Million Underwritten Public Offering
15/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
15/02/2019
OCALA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical [...]

Pages